Prosecution Insights
Last updated: November 04, 2026
Application No. 18/239,052

Multi-Specific Molecules

Final Rejection §102§103§112
Filed
Aug 28, 2023
Priority
Feb 26, 2016 — AU 2016900708 +4 more
Examiner
BRISTOL, LYNN ANNE
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Imunexus Therapeutics Limited
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
737 granted / 1163 resolved
+3.4% vs TC avg
Strong +40% interview lift
Without
With
+39.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
78 currently pending
Career history
1233
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
48.5%
+8.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1163 resolved cases

Office Action

§102 §103 §112
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims 1. Claims 1-43 are the original claims filed on 8/28/2023. In the Preliminary amendment of 8/28/2023, claims 1-43 are canceled and claims 44-61 are added. In the Response of 7/27/2026, Claims 44, 49-51, 53, 56, 57, and 60 are amended and claims 45-48 and 59 are cancelled. Claims 44, 49-58, and 60-61 are the claims under examination. Applicants amendment of the claims raises new grounds for rejection. The Office Action is final. Priority 2. USAN 18/239,052, filed 08/28/2023 is a Continuation of 16/946,451, filed 06/22/2020, now abandoned, 16/946,451 is a Continuation of 16/079,949, filed 08/24/2018, now abandoned, 16/079,949 is a National Stage entry of PCT/AU2017/050168, International Filing Date: 02/27/2017, and which claims foreign priority to AU 2016900708, filed 02/26/2016, and claims foreign priority to AU 2016900709, filed 02/26/2016. The priority claim for a filing date of 02/26/2016 is granted. Information Disclosure Statement 3. As of 9/8/2026, a total of two (2) IDS is filed: 8/12/2024; and 7/27/2026. The corresponding initialed and dated 1449 form is considered and of record. Withdrawal of Objections Specification 4. The objection to the disclosure because of informalities is withdrawn. Both clean and marked-up copies of the specification are filed with the Response. a) The specification is amended to include sequence identifiers for amino acid sequences > 4 amino acids. b) The figure legend for Figure 1(c) is amended to include the sequence identifier for the amino acid sequence > 4 amino acids in length that is SEQ ID NO: 5; the figure legend is amended to clarify panels A-C in the figure. c) The specification is amended to rectify the improper use of the term, i.e., Tris, Biacore, Sepharose, BLITz Biosensor, ATCC, Expi293, Opti-MEM, ExpiFectamine, HiSpeed, ElectroTen-Blue, Cellfectin, Lipofectamine, Dynabeads, nanobody, NCBI, Uniprot, forteBio, pellicon, cellfectin, affibody, DARPin, which is a trade name or a mark used in commerce. 5. The objection to the abstract of the disclosure is moot in view of the amendment of claim 44 to delete the limitation for a scaffold. Claim Objections 6. The objection to Claims 44-61 because of informalities is moot for the canceled claims and withdrawn for the pending claims. a) Claim 44 is amended to delete the phrase in (ii) “…or antigen-biding fragment thereof” b) Claims 44-61 are amended to delete the phrase antigen-binding fragment thereof,” Withdrawal of Rejections Claim Rejections - 35 USC § 112(b) 7. The rejection of Claims 44-61 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is moot for the canceled claims and withdrawn for the pending claims. a) Claims 44-61 are amended in claim 44 to delete the portion of the phrase for the polypeptide chain “ b) Claims 44-61 are amended to replace “human CTLA-4 [form]” with the structure for the sequence of SEQ ID NO: 5. c) Claim 47 is canceled. d) Claim 48 is canceled. e) Claim 53 is amended to delete "polypeptide". f) Claims 56 is amended to delete the parentheses from the text for “or BDM pair.” g) Claim 57 is amended to delete "polypeptide". h) Claim 58 is amended for proper punctuation. i) Claim 59 is canceled and claim 60 is amended to depend from claim 44. Double Patenting 8. The rejection of Claims 44-61 on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 11345736 (IDS) is moot for the canceled claims and withdrawn for the pending claims. The terminal disclaimer filed on 7/27/2026 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Patent No. 11345736 has been reviewed and is accepted. The terminal disclaimer has been recorded. Claim Rejections - 35 USC § 102 9. The rejection of Claims 44, 49-52, 57-59 and 61 under 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) as being anticipated by Tomlinson et al. (WO2008/096158; IDS) is withdrawn. Applicants amendment requires that at least one BDM is coupled via its N-terminus to a C-terminus to the non-antibody protein or peptide and obviates the rejection. Rejections Withdrawn-in-Part/ Maintained-in-part The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Written Description 10. The rejection of Claims 44, 49-58, and 60-61 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement is: Moot for canceled claims 45-48 and 59 Withdrawn-in-part: for claims 44, 49-58, and 60-61 regards the amendment to claim 44 to incorporate, inter alia, the subject matter of canceled claim 59. Maintained-in-part: for claims 44, 49-58, and 60-61 drawn to the sequence of SEQ ID NO: 5 wherein X is any amino acid residue for any one of the BL for the multi-specific molecule. Applicants allege amendment to claim 44 to incorporate the subject matter of claim 59 which recites the sequence and therefore structure of the human CTLA-4 scaffold delineates the location of the binding loops. The skilled person is provided with direction as to where to include a heterologous sequence to provide binding to a target epitope and a principle of general application that is shared across the genus of multi-specific molecules. Response to Arguments The specification teaches the modifications to the amino acids for the binding loops that are infinite in scope: [0077] In another example a single exposed binding loop, two exposed binding loops or all three exposed binding loops of the native BDM scaffold may be modified by amino acid substitution, addition or deletion, and/or by any change to one or more physical characteristics (e.g. size, shape, charge, hydrophobicity etc.). [0078] In a further example, the exposed binding loop (BL1) sequence ASPGKATE (SEQ ID NO:2) or ASPGKYTE (SEQ ID NO:7), and/or exposed loop (BL2) sequence MMGNE (SEQ ID NO:3) and/or the exposed binding loop (BL3) sequence ELMYPPPYY (SEQ ID NO:4) of the native human CTLA-4 VLD sequence is modified by amino acid substitution, addition or deletion or replaced with a heterologous sequence. Notably, the specification teaches the binding loops function in a similar manner to the complementarity determining regions (CDRs) in antibody variable domains at [0223] A “BL sequence” is surface polypeptide loop structure or region that function in a similar manner to the complementarity determining regions (CDRs) in antibody variable domains that bind to specific antigens. Three antigen binding loop sequences (referred to herein as BL-1, BL-2 and BL-3 respectively) are present in the BDM and they sit within a scaffold sequence which provides the required three dimensional conformation of the loop sequences. Native BL sequences can be replaced with one or more corresponding antibody CDRs which can be grafted onto the scaffold. Diversity can be introduced into the BL sites of the BDM by randomising the amino acid sequence of the specific loops of the scaffold e.g. by introducing NNK codons followed by selection for desired binding characteristics using, for example, display technologies. This mechanism is similar to natural selection of high affinity, antigen-specific antibodies. The absence of any teaching in the specification for a canonical structure for any one of the BLs much less the scope of “any amino acid” for the instant claims renders the inventive subject matter reach-through and a wish to know. See MPEP 2163 (II)(A)(3)(a)(i): “Thus, the written description requirement may be satisfied through disclosure of function and minimal structure when there is a well-established correlation between structure and function. In contrast, without such a correlation, the capability to recognize or understand the structure from the mere recitation of function and minimal structure is highly unlikely. In this latter case, disclosure of function alone is little more than a wish for possession; it does not satisfy the written description requirement. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406 (written description requirement not satisfied by merely providing “a result that one might achieve if one made that invention”); In re Wilder, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming a rejection for lack of written description because the specification does “little more than outline goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate”).” Has Applicant provided a common structure sufficient to visualize the genus? The meaning of a BL could encompass natural, unnatural, synthetic of even mimetic amino acids in the form of substitutions and/or insertions. The ordinary artisan cannot envisage what structures are intended for the phrase “any amino acid” that would possess multi-specificity for binding two or more different antigens. Status of the Art for Predicting antibody binding AS the specification explicitly analogizes a BL to an antibody CDR, the POSA could reasonably conclude that the specification does NOT support the full scope of the claims. It is unclear what structural features any one of the BL needs to share to maintain binding affinity and stability for any first target much less in coupled form with the pharmacologically active protein or peptide to the second target. Even in 2021, and for antibody CDR variation, it is still not understood how to predict with certainty what modifications can be made to a primary antibody sequence such that binding is maintained. “[T]he major test of understanding is whether the changes associated with antibody maturation can be predicted with any reasonable accuracy, and whether there is sufficient information for developing therapeutic antibodies,” Vajda et al., “Progress toward improved understanding of antibody maturation,” Current Opinion in Structural Biology, 67 pp. 226-231 (2021 (PTO 892)) at p. 226, col. 2, lines 20-24. As recently as 2020, researches were still speculating as to how to reliably identify further putative binders from antibody sequence data, see, e.g., Marks et al., “How repertoire data are changing antibody science,” J. Biol. Chem. 295(29) 9823-9837 (2020 (PTO 892)), acknowledging that “there is a vast amount of the antibody sequence space that remains unknown,” p. 9831, col. 2, para. 2. Even though the protein sequence of extracellular CTL4 was known in the art, this would not have been translated into knowledge of the genus of BL that could possibly engage just any target (element (i) of Claim 44). Computational and machine learning approaches for sequence-based prediction of paratope-epitope interactions are accumulating, but “it remains unclear whether antibody-antigen binding is predictable” (Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021 at p. 2, col. 2, para. 2 (PTO 892)). The current state of the art continues to work toward finding an effective and efficient prediction tool for reliably assigning antibody structure based on known target epitopes. See e.g., Lo et al., “Conformational epitope matching and prediction based on protein surface spiral features,” BMC Genomics volume 22, Article number: 116 (2021 (PTO 892)) (disclosing new algorithms that calculate physicochemical properties, such as polarity, charge or the secondary structure of residues within the targeted protein sequences, and then applying quantitative matrix analyses or machine-learning algorithms to predict linear and conformational epitopes). It is asserted that neither the specification nor the state of art at the time of filing disclosed structural features common to the members of the genus of BL for reliably assigning different amino acids based on sequence data from limited EC-CTLA4, which would support the premise that the inventors possessed the full scope of the claimed invention. Rejections Maintained Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 11. The rejection of Claims 44-46, 49-52, 54-58, and 60-61 under 35 U.S.C. 103 as being unpatentable over Tomlinson et al. (WO2008/096158; IDS) is moot for canceled claims 46 and 59 and maintained for the pending claims. The teachings of Tomlinson were set forth in full in the previous office action. Those teachings and the reasons why they render the claimed invention unpatentable are incorporated here in full. (A) Applicants allege the presence of BDMs at a C-terminus of the protein or peptide serves to direct the poorly therapeutic protein or peptide to the site in which its activity is required. In the present case, the use of the CTLA-4 BDMs may serve to enhance one or more characteristics of the protein or peptide such as avidity or cell penetration. Response to Arguments The underlying structural or functional features that produce those results must be present in the claims. MPEP § 716.02(d)) stating in part “the objective evidence of unexpected results must be commensurate in scope with the claims.” (B) Applicants allege the examples and figures demonstrate dual or trivalent binding with modified CTLA-4 molecules attached to a protein, e.g., human serum albumin (Example 8). This could not have been predicted from the disclosures of Tomlinson et al which used smaller molecules such as dAb. Not only were the inventors able to show that such constructs remained intact with correctly associated subunits but that each binding molecule was capable of independent and bi-specific or tri-specific binding; and the rejection of record are prophetic, therefore the claimed invention provided unexpected results that could not have been predicted from the general and prophetic guidance of Tomlinson. Response to Arguments The present claims are not commensurate in scope with the evidence of unexpected results from Example 8. It is not only clear that the particular scaffold used (i.e., SEQ ID NO: 5) was key to providing a molecule that could bind two or more specificities, but also the peptide linker that linked the N-terminus of the CLTL-4 scaffold to the C-terminus of the non-antibody protein or the peptide. None of the present claims are commensurate in scope with the evidence of unpredictability/ unexpected results provided. Accordingly, the rejection is maintained as applied to the amended claims. Therefore , after reconsideration of the claims, Applicants arguments and the intrinsic evidence of record, the rejection is maintained for the reasons of record and as elaborated herein above. New Grounds for Rejection Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 12. Claims 44, 49-58, and 60-61 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. a) Claims 44, 49-58, and 60-61 recite the limitation "wherein sequences of the three BLs are modified or replaced relative to their corresponding native sequence in the scaffold for selective binding to the first target antigen or epitope" in Claim 44(i). There is insufficient antecedent basis for this limitation in the claim. The first target antigen or epitope is replaced in element (i) of claim 44 to “a first target.” b) Claim 58 recites the limitation "wherein the VLD scaffold comprises a framework sequence having… ". There is insufficient antecedent basis for this limitation in the claim. Claim 44 is amended to delete the limitation “a V-like domain (VLD) scaffold” and therefore the entirety of claim 58 finds no antecedency in the claim from which it depends. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 13. Claims 44, 49-58, and 60-61 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Amended claim 44 recites X of the three BL is any amino acid residue of between 5 and 15 residues (“wherein X is any amino acid residue, n is a number between 5 and 15…”) then goes on to recite “wherein sequences of the three BLs are modified or replaced relative to their corresponding native sequence.” The amendment is narrower in scope than the “wherein” clause for the three BL sequences where any modification or replacement anywhere within the sequence is contemplated. Accordingly, the BLs are not excluded from any modification or replacement. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion 14. No claims are allowed. 15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYNN A. BRISTOL whose telephone number is (571)272-6883. The examiner can normally be reached Mon-Fri 9 AM-5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Julie can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LYNN A BRISTOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Aug 28, 2023
Application Filed
Mar 25, 2026
Non-Final Rejection mailed — §102, §103, §112
Jul 27, 2026
Response Filed
Sep 14, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780949
ANTI-CLAUDIN 18.2 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
3y 9m to grant Granted Nov 03, 2026
Patent 12723105
MONOSPECIFIC AND MULTI-SPECIFIC ANTIBODIES
4y 5m to grant Granted Sep 01, 2026
Patent 12723106
PROTEASE-PROCESSED MOLECULES
4y 0m to grant Granted Sep 01, 2026
Patent 12723083
ANTI-CD3/ANTI-CD28 BISPECIFIC ANTIGEN BINDING MOLECULES
3y 8m to grant Granted Sep 01, 2026
Patent 12708667
COMPOSITIONS AND METHODS CONCERNING COMBINATIONS OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER
5y 6m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+39.7%)
3y 4m (~2m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1163 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month